Ophthalmic Drugs Contract Manufacturing Market 2030

• Posted by Stella Wilson May 27, 2021 - Filed in Health - #Ophthalmic Drugs Contract Manufacturing Market  - 847 views

  More than 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis, working at different scales of operation, for a wide range of ophthalmic APIs and drug FDFs, claims Roots Analysis

  Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.

  The USD 1.7 billion financial opportunity (by 2030) within the Ophthalmic Drugs Contract Manufacturing Market has been analyzed across the following segments:

  Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

  Get Detailed Analysis:  https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

  Key Market Insights

  • Over 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis, working at different scales of operation, for a wide range of ophthalmic APIs and drug FDFs
  • The market is fragmented, featuring the presence of both established players and small firms based in different geographies that claim to be capable of manufacturing ophthalmic products
  • Presently, majority of the CMOs are offering services for ophthalmic drug FDFs packaged in a variety of formats; popular types of containers include glass / plastic bottles, ointment tubes and ampoules / vials
  • In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities
  • Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and maintain a competitive edge
  • In the past few years, over 10,700 trials, enrolling approximately 4.6 million patients, suffering from a wide range of chronic eye conditions, have been registered across the globe by different sponsors
  • Most of the installed, global ophthalmic drug manufacturing capacity belongs to larger and more established CMOs, accounting for over 80% of available capacity across various geographies
  • The demand for manufacturing services for ophthalmic drug products is expected to increase in the coming years; we believe stakeholders may have to expand their respective capacities to ensure consistent supply
  • We expect ophthalmic drug developers to continue to outsource their development and manufacturing operations in the short to mid-term, causing service-based revenues to grow at an annualized rate of over 8%
  • In the long-term, the projected opportunity is anticipated to be well distributed across various packaging formats, scales of operation and sizes of contract service providers
  • Eminent representatives from prominent ophthalmic drug contract manufacturing companies confirm the importance of outsourcing, highlighting prevalent and anticipated trends within this domain

  Type of product

  • Ophthalmic API
  • Ophthalmic drug FDF

  Type of FDF manufactured

  • Solid
  • Semi-solid
  • Liquid / suspension

  Type of primary packaging

  • Ampoule / vial
  • Glass / plastic bottle
  • Ointment tube
  • Blister packing
  • Other forms

  Scale of manufacturing

  • Clinical
  • Commercial

  Company size

  • Small
  • Mid-sized
  • Large
  • Very large

  Target disease indication

  • Age-related macular degeneration
  • Dry eye
  • Glaucoma
  • Other disease segments

  Key geographical regions

  • North America (US, Canada and Mexico)
  • Europe (UK, Germany, France, Spain, Italy and rest of Europe)
  • Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
  • Rest of the world

  Request for Customization: https://www.rootsanalysis.com/reports/294/request-customization.html

  The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Akorn
  • Akums
  • Bal Pharma
  • Catalent
  • Cayman Chemical
  • Entod Pharmaceuticals
  • Farmigea
  • Glenmark Pharmaceuticals
  • Indiana Ophthalmics
  • Lomapharm
  • Medichem
  • Pillar5 Pharma
  • Recipharm
  • Salvat
  • Sterling Pharmaceutical Services
  • Sunways India

  Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Current Market Landscape
  5. Company Competitiveness Analysis
  6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles
  7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles
  8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles
  9. Clinical Trial Analysis
  10. Capacity Analysis
  11. Demand Analysis
  12. Market Forecast
  13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies
  14. SWOT Analysis
  15. Survey Analysis
  16. Executive Insights
  17. Future Growth Opportunities
  18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers
  19. Appendix 2: Tabulated Data
  20. Appendix 3: List of Companies and Organizations

  Get Latest PDF Sample of this Report:

  https://www.rootsanalysis.com/reports/294/request-sample.html    

  About Roots Analysis

  Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

  Contact Information

  Roots Analysis Private Limited

  Gaurav Chaudhary

  +1 (415) 800 3415

  Gaurav.Chaudhary@rootsanalysis.com

   

  Also have a Look on Our Upcoming Research Reports

  Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

  Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market Trends and Global Forecasts, 2021-2030

  Spinal Muscular Atrophy Market, 2021-2031

  Dravet Syndrome Market, 2021-2031

  Hypertrophic Cardiomyopathy Market 2021-2031